LitAlert ~~

    • Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Feb 7.

    Original research:

    A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

    • DNA damage-induced sumoylation of Sp1 induces its interaction with RNF4 and degradation in S phase to remove 53BP1 from DSBs and permit HR.
    • Swift ML, Azizkhan-Clifford J.
    • DNA Repair (Amst). 2022 Feb 1;111:103289. doi: 10.1016/j.dnarep.2022.103289. Epub ahead of print.